<DOC>
	<DOCNO>NCT01094522</DOCNO>
	<brief_summary>Study Population : Neonates , infant child birth 5 year age undergoing cardiac surgery CPB . The use methadone provide analgesia may increase due advantage compare commonly use opioid analgesic drug . While efficacy methadone report adult , paucity information neonates infant . In latter population , fentanyl morphine commonly use opioid analgesia follow major surgery , methadone frequently use wean opioid dependent tolerant patient , spite paucity knowledge methadone pharmacology population . There several clinical problem associate fentanyl morphine , methadone may offer superior efficacy few side effect agent . We propose study pharmacokinetics ( PK ) pharmacodynamics ( PD ) methadone neonates infant intensive care unit follow cardiac surgery .</brief_summary>
	<brief_title>Measuring Amount Methadone Morphine Blood Neonates , Infants &amp; Children After Cardiac Surgery .</brief_title>
	<detailed_description>Treatment : Fentanyl administer intraoperative analgesia treat anesthesiologist dose range 25 - 50 mcg/kg . No intraoperative opioids give . Subjects receive intravenous methadone morphine ( `` study drug '' ) deliver initial IV `` bolus '' injection follow nurse-administered patient control analgesia ( PCA ) device postoperative pain period 24 hour . The initial dose study drug 0.2 mg/kg IV administer follow admission ICU surgery . The study drug give dose 0.035 mg/kg IV need q30min via PCA . The study drug may increase decreased increment 20-25 % accord discretion investigator need maintain FLACC pain assessment tool &lt; 4 . Subjects also receive lorazepam 0.025 mg/kg IV q2hr need agitation indicate specific criterion . The study drug discontinue 24 hour facilitate `` wash '' sample determination elimination half-life . Beginning 24 hour , fentanyl use analgesia equianalgesic dose determine investigator base upon current PCA `` study drug '' dose . Measurements Monitoring : - Blood sample obtain measurement concentration methadone ( methadone group ) morphine metabolite , morphine-3-glucuronide morphine-6-glucuronide ( morphine group ) , prior administration initial bolus dose ( = 0 ) = 5 min , 15 min , 30 min , 60 min , 2 hr , 4 hr 6 hr ; thereafter , blood sample obtain measurement every 6 hr 90 hr accord availability vascular access phlebotomy . - Continuous monitoring : temperature ( rectal ) , electrocardiogram , heart rate , systemic arterial blood pressure , central venous blood pressure , respiratory rate , oxygen saturation ( pulse oximetry ) - Intermittent recording ( q1hr ) : urine output - Lab Tests ( baseline [ prior study procedure ] 24 hour initial dose study medication ) : arterial blood gas tension , arterial lactate , Hb/Hct , BUN/Cr , glucose , AST , ALT - 12 lead ECG hour 24 determination QTc . - The Faces , Legs , Activity , Cry , Consolability ( FLACC ) Scale recode every hour , precede every study medication PCA dose 24 hour . - Subject follow 90 hour record time extubation , re-intubation necessary , reason re-intubation . Primary Endpoints : Pharmacokinetics methadone morphine , include metabolite ( morphine-3-glucuronide morphine-6-glucuronide ) Secondary Endpoints : - Pain score ( FLACC ) 24 hour study period - Amount study drug administer 24-hour dosing period - Changes heart rate , systemic arterial blood pressure laboratory test value</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Neonates , infant child birth 5 year age undergoing mechanical ventilation follow cardiac surgery congenital heart disease . Congenital heart lesion include `` two ventricle repair '' , include tetralogy Fallot , transposition great artery , `` unobstructed '' total anomalous pulmonary venous return , truncus arteriosus , atrioventricular canal defect ventricular septal defect . Subjects exclude study prematurity ( gestational age &lt; 37 week ) , weight &lt; 3.0 kg , severe hepatic dysfunction ( elevation conjugate bilirubin &gt; 2 , AST/ALT &gt; 200 IU/L ) , significant renal dysfunction ( serum Cr &gt; 1.5 mg/dL ) , participation within 30 day study entry within 5 time halflife , whichever longer , another investigational drug study , previous participation study . Patients exclude received opioids 12 hour 48hour period prior surgery . In addition , patient exclude history clinically significant medical problem , , opinion investigator , would interfere study participation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>